A Study of Continuous Oral Contraceptives and Doxycycline

Completed · Not applicable · Has a placebo group

Conditions studied: Contraceptives, Oral

In brief

The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only contraception but has not been studied in combined hormonal contraception.

Key facts

Study ID

NCT00480532

Run by

Oregon Health and Science University

People needed

131

Starts

2007-05-01

Expected to finish

2011-05-01

Last updated by the study team

2014-10-22

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• General good health
• Willing and able to agree to randomization and sign informed consent
• Currently having regular menstrual cycles (24-36 days), with combined cyclic hormonal method (COCs, Nuva Ring, Ortho Evra), without intermenstrual bleeding in last 2 years.

You may not qualify if…

• Intrauterine device (IUD) in place
• Abnormal pap smear that has not been treated or followed up
• Those with hypersensitivity reactions to doxycycline or any of the tetracyclines
• Use of depomedroxyprogesterone acetate within 9 months of the start of the study.
• Use of hormonal medications (excluding cyclic contraceptives and plan B) within 2 months of the start of the study.
• Any one unwilling to keep a daily menstrual diary or otherwise unwilling to follow the study criteria
• Currently taking medications that interfere with COCs (rifampin, carbamazepine, St. Johns wort)
• Currently has a progestin implant
• Positive Gonorrhea or Chlamydia cultures at enrollment examination
• Smoking more than 5 cigarettes per month
• Any medical condition that is a contraindication to the use of COCs in accordance with product labeling including:
• History of thrombophlebitis, deep venous thrombosis, thrombogenic vasculopathies, thrombogenic rhythm disorders or thromboembolic disorders
• Current or past history of cerebrovascular or coronary artery disease
• Scheduled major surgery in the next six months with prolonged immobilization
• Diabetes with vascular involvement
• Headache with focal neurologic symptoms
• Uncontrolled hypertension
• Suspected or known carcinoma of the breast or personal history of breast cancer
• Carcinoma of the endometrium or other known or suspected estrogen dependent neoplasms
• Undiagnosed genital bleeding
• History of cholestatic jaundice of pregnancy or cholestatic jaundice with prior oral contraceptive use
• Hepatic adenoma or carcinoma or active liver disease if liver function has not returned to normal
• Known or suspected pregnancy
• Hypersensitivity to estrogen or progesterone containing products

Where it is running

• University of Hawaii (UH) — Honolulu, Hawaii, United States
• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.